Status:
COMPLETED
Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms
Lead Sponsor:
Institut Bergonié
Conditions:
Upper Gingival Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Hypothesis: Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive biomarkers of Ce...
Detailed Description
Hypothesis: Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive biomarkers of Ce...
Eligibility Criteria
Inclusion
- Patient with recurrent or metastatic squamous cell carcinomas of the upper aero-digestive tract
- Patient with loco-regional extension not readily treatable
- 18 years
- Follow up in participant center
- Patient information and consent for study participation
- Patient presented in multidisciplinary meeting (RCP) in Aquitaine and for whom a treatment containing cetuximab has been proposed
- Belong to a social security system
Exclusion
- Pregnancy
- Patient with psychological, social, family or geographical reason, who could not be treated or monitored regularly by study criteria,
- Patients deprived of liberty or under guardianship or who could not give consent for study participation
- Inclusion in another study
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT01827956
Start Date
August 1 2009
End Date
December 1 2013
Last Update
December 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Bergonié
Bordeaux, Aquitaine, France, 33000